Kalaris Therapeutics, Inc. (KLRS)
4.10
-0.05
(-1.20%)
USD |
NASDAQ |
Aug 24, 16:00
4.08
-0.02
(-0.49%)
After-Hours: 20:00
Kalaris Therapeutics Total Liabilities (Quarterly) : 41.87M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 41.87M |
| March 31, 2026 | 41.25M |
| December 31, 2025 | 42.92M |
| September 30, 2025 | 39.31M |
| June 30, 2025 | 39.73M |
| March 31, 2025 | 39.22M |
| December 31, 2024 | 102.78M |
| September 30, 2024 | 1.412M |
| June 30, 2024 | 10.70M |
| March 31, 2024 | 23.70M |
| December 31, 2023 | 45.02M |
| September 30, 2023 | 52.98M |
| June 30, 2023 | 53.58M |
| March 31, 2023 | 50.51M |
| Date | Value |
|---|---|
| December 31, 2022 | 52.56M |
| September 30, 2022 | 40.47M |
| June 30, 2022 | 41.86M |
| March 31, 2022 | 39.42M |
| December 31, 2021 | 61.33M |
| September 30, 2021 | 49.23M |
| June 30, 2021 | 25.04M |
| March 31, 2021 | 20.91M |
| December 31, 2020 | 17.76M |
| September 30, 2020 | 19.81M |
| June 30, 2020 | 16.01M |
| March 31, 2020 | 15.58M |
| December 31, 2019 | 17.80M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Replimune Group, Inc. | 146.80M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 99.54M |
| Shareholders Equity (Quarterly) | 57.67M |
| Debt to Equity Ratio | 0.0243 |
| Current Ratio | 10.92 |
| Net Debt Paydown Yield | -0.29% |